Journal cover Journal topic
Journal of Bone and Joint Infection An open-access journal of the European Bone and Joint Infection Society and the MusculoSkeletal Infection Society
Journal topic

Journal metrics

h5-index value: 15
h5-index15
Download
Short summary
Costs related to off-label expensive antibiotics used to treat bone and joint infections (BJIs) in a referral centre in France were analysed in this cohort study. Despite the large increase in the number of patients treated with these antibiotics, the overall costs remained stable (approximately EUR 1 million) and were helped by the appearance of generic molecules at lower prices. Production of generic antibiotics at low cost is essential to limit the financial burden of the management of BJIs.
JBJI | Articles | Volume 6, issue 8
J. Bone Joint Infect., 6, 337–346, 2021
https://doi.org/10.5194/jbji-6-337-2021
J. Bone Joint Infect., 6, 337–346, 2021
https://doi.org/10.5194/jbji-6-337-2021

Original full-length article 07 Sep 2021

Original full-length article | 07 Sep 2021

Cost of off-label antibiotic therapy for bone and joint infections: a 6-year prospective monocentric observational cohort study in a referral centre for management of complex osteo-articular infections

Truong-Thanh Pham et al.

Viewed

Total article views: 236 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
195 37 4 236 2 2
  • HTML: 195
  • PDF: 37
  • XML: 4
  • Total: 236
  • BibTeX: 2
  • EndNote: 2
Views and downloads (calculated since 07 Sep 2021)
Cumulative views and downloads (calculated since 07 Sep 2021)

Viewed (geographical distribution)

Total article views: 206 (including HTML, PDF, and XML) Thereof 206 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 
Latest update: 26 Oct 2021
Publications Copernicus
Download
Short summary
Costs related to off-label expensive antibiotics used to treat bone and joint infections (BJIs) in a referral centre in France were analysed in this cohort study. Despite the large increase in the number of patients treated with these antibiotics, the overall costs remained stable (approximately EUR 1 million) and were helped by the appearance of generic molecules at lower prices. Production of generic antibiotics at low cost is essential to limit the financial burden of the management of BJIs.
Citation